125 related articles for article (PubMed ID: 9834241)
1. CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents.
Britos-Bray M; Ramirez M; Cao W; Wang X; Liu PP; Civin CI; Friedman AD
Blood; 1998 Dec; 92(11):4344-52. PubMed ID: 9834241
[TBL] [Abstract][Full Text] [Related]
2. CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors.
D'Costa J; Chaudhuri S; Civin CI; Friedman AD
Leukemia; 2005 Jun; 19(6):921-9. PubMed ID: 15815715
[TBL] [Abstract][Full Text] [Related]
3. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
Bernardin F; Yang Y; Civin CI; Friedman AD
Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
[TBL] [Abstract][Full Text] [Related]
4. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
5. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
6. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
7. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
8. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells.
Cao W; Britos-Bray M; Claxton DF; Kelley CA; Speck NA; Liu PP; Friedman AD
Oncogene; 1997 Sep; 15(11):1315-27. PubMed ID: 9315100
[TBL] [Abstract][Full Text] [Related]
9. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
10. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
12. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation.
Cao W; Adya N; Britos-Bray M; Liu PP; Friedman AD
J Biol Chem; 1998 Nov; 273(47):31534-40. PubMed ID: 9813068
[TBL] [Abstract][Full Text] [Related]
13. The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis.
Kamikubo Y; Hyde RK; Zhao L; Alemu L; Rivas C; Garrett LJ; Liu PP
Blood; 2013 Jan; 121(4):638-42. PubMed ID: 23152542
[TBL] [Abstract][Full Text] [Related]
14. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.
Pulikkan JA; Hegde M; Ahmad HM; Belaghzal H; Illendula A; Yu J; O'Hagan K; Ou J; Muller-Tidow C; Wolfe SA; Zhu LJ; Dekker J; Bushweller JH; Castilla LH
Cell; 2018 Jun; 174(1):172-186.e21. PubMed ID: 29958106
[TBL] [Abstract][Full Text] [Related]
15. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
16. Cbfbeta-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B-cell development.
Kuo YH; Gerstein RM; Castilla LH
Blood; 2008 Feb; 111(3):1543-51. PubMed ID: 17940206
[TBL] [Abstract][Full Text] [Related]
17. CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.
Cordonnier G; Mandoli A; Cagnard N; Hypolite G; Lhermitte L; Verhoeyen E; Asnafi V; Dillon N; Macintyre E; Martens JHA; Bond J
Cell Rep; 2020 Jan; 30(2):299-307.e3. PubMed ID: 31940477
[TBL] [Abstract][Full Text] [Related]
18. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability.
Wunderlich M; Krejci O; Wei J; Mulloy JC
Blood; 2006 Sep; 108(5):1690-7. PubMed ID: 16670269
[TBL] [Abstract][Full Text] [Related]
19. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
Adya N; Stacy T; Speck NA; Liu PP
Mol Cell Biol; 1998 Dec; 18(12):7432-43. PubMed ID: 9819429
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]